PH12021551975A1 - Use of vibegron to treat overactive bladder - Google Patents
Use of vibegron to treat overactive bladderInfo
- Publication number
- PH12021551975A1 PH12021551975A1 PH1/2021/551975A PH12021551975A PH12021551975A1 PH 12021551975 A1 PH12021551975 A1 PH 12021551975A1 PH 12021551975 A PH12021551975 A PH 12021551975A PH 12021551975 A1 PH12021551975 A1 PH 12021551975A1
- Authority
- PH
- Philippines
- Prior art keywords
- vibegron
- overactive bladder
- treat overactive
- treat
- directed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820230P | 2019-03-18 | 2019-03-18 | |
| US201962830302P | 2019-04-05 | 2019-04-05 | |
| US201962842435P | 2019-05-02 | 2019-05-02 | |
| US201962885767P | 2019-08-12 | 2019-08-12 | |
| US201962897019P | 2019-09-06 | 2019-09-06 | |
| US201962904429P | 2019-09-23 | 2019-09-23 | |
| PCT/IB2020/052484 WO2020188505A1 (en) | 2019-03-18 | 2020-03-18 | Use of vibegron to treat overactive bladder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021551975A1 true PH12021551975A1 (en) | 2022-07-04 |
Family
ID=70166082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2021/551975A PH12021551975A1 (en) | 2019-03-18 | 2020-03-18 | Use of vibegron to treat overactive bladder |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230027066A1 (https=) |
| EP (1) | EP3941473A1 (https=) |
| JP (2) | JP2022524576A (https=) |
| KR (2) | KR20210142004A (https=) |
| CN (2) | CN121489955A (https=) |
| AU (2) | AU2020243514A1 (https=) |
| BR (1) | BR112021017198A2 (https=) |
| CA (1) | CA3129024A1 (https=) |
| IL (1) | IL285910A (https=) |
| MX (1) | MX2021009488A (https=) |
| PH (1) | PH12021551975A1 (https=) |
| SG (1) | SG11202108810YA (https=) |
| TW (2) | TW202102221A (https=) |
| WO (1) | WO2020188505A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3634420A1 (en) | 2017-06-06 | 2020-04-15 | Urovant Sciences GmbH | Use of vibegron to treat overactive bladder |
| SG11202103662VA (en) | 2018-12-05 | 2021-06-29 | Urovant Sciences Gmbh | Vibegron for the treatment of overactive bladder symptoms |
| TW202245781A (zh) * | 2021-02-16 | 2022-12-01 | 瑞士商優洛凡特科學公司 | 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
| ES2584427T3 (es) | 2011-10-27 | 2016-09-27 | Merck Sharp & Dohme Corp. | Proceso para la preparación de agonistas beta 3 y productos intermedios |
| WO2013062881A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Process for making beta 3 agonists and intermediates |
| RS59402B1 (sr) | 2013-03-15 | 2019-11-29 | Merck Sharp & Dohme | Postupak za pripremu beta 3 agonista i međuproizvoda |
| JP6197971B1 (ja) * | 2016-04-22 | 2017-09-20 | 小野薬品工業株式会社 | Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤 |
| US20170348288A1 (en) * | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder |
| US10057209B2 (en) * | 2016-07-28 | 2018-08-21 | Qualcomm Incorporated | Time-sequenced multi-device address assignment |
| JP7670461B2 (ja) * | 2017-06-06 | 2025-04-30 | ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング | 過活動膀胱の治療のためのビベグロンの投薬 |
| EP3634420A1 (en) * | 2017-06-06 | 2020-04-15 | Urovant Sciences GmbH | Use of vibegron to treat overactive bladder |
| EP3583905A1 (en) * | 2018-06-20 | 2019-12-25 | Arthrex Inc | Percutaneous targeting device |
-
2020
- 2020-03-18 JP JP2021545837A patent/JP2022524576A/ja active Pending
- 2020-03-18 US US17/440,612 patent/US20230027066A1/en active Pending
- 2020-03-18 SG SG11202108810Y patent/SG11202108810YA/en unknown
- 2020-03-18 MX MX2021009488A patent/MX2021009488A/es unknown
- 2020-03-18 BR BR112021017198A patent/BR112021017198A2/pt unknown
- 2020-03-18 EP EP20716934.3A patent/EP3941473A1/en active Pending
- 2020-03-18 TW TW109109041A patent/TW202102221A/zh unknown
- 2020-03-18 KR KR1020217033037A patent/KR20210142004A/ko not_active Ceased
- 2020-03-18 AU AU2020243514A patent/AU2020243514A1/en not_active Abandoned
- 2020-03-18 CN CN202511459167.9A patent/CN121489955A/zh active Pending
- 2020-03-18 PH PH1/2021/551975A patent/PH12021551975A1/en unknown
- 2020-03-18 WO PCT/IB2020/052484 patent/WO2020188505A1/en not_active Ceased
- 2020-03-18 TW TW113116798A patent/TW202506129A/zh unknown
- 2020-03-18 KR KR1020267009764A patent/KR20260049872A/ko active Pending
- 2020-03-18 CA CA3129024A patent/CA3129024A1/en active Pending
- 2020-03-18 CN CN202080036713.7A patent/CN113840607A/zh active Pending
-
2021
- 2021-08-26 IL IL285910A patent/IL285910A/en unknown
-
2025
- 2025-02-07 JP JP2025018962A patent/JP2025084777A/ja active Pending
- 2025-10-23 AU AU2025256180A patent/AU2025256180A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113840607A (zh) | 2021-12-24 |
| SG11202108810YA (en) | 2021-10-28 |
| AU2020243514A1 (en) | 2021-08-26 |
| AU2025256180A1 (en) | 2025-11-13 |
| MX2021009488A (es) | 2021-09-21 |
| TW202506129A (zh) | 2025-02-16 |
| WO2020188505A1 (en) | 2020-09-24 |
| CN121489955A (zh) | 2026-02-10 |
| JP2022524576A (ja) | 2022-05-09 |
| EP3941473A1 (en) | 2022-01-26 |
| JP2025084777A (ja) | 2025-06-03 |
| BR112021017198A2 (pt) | 2021-11-16 |
| CA3129024A1 (en) | 2020-09-24 |
| TW202102221A (zh) | 2021-01-16 |
| IL285910A (en) | 2021-10-31 |
| KR20210142004A (ko) | 2021-11-23 |
| KR20260049872A (ko) | 2026-04-14 |
| US20230027066A1 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011653A (es) | Métodos de tratamiento para el abuso de sustancias. | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| PH12019500845A1 (en) | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| MX2023002323A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2024002360A (es) | Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales. | |
| PH12021551975A1 (en) | Use of vibegron to treat overactive bladder | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| WO2023081830A3 (en) | Compositions and treatments with nirogacestat | |
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| MX2021001264A (es) | Métodos para tratar la vejiga hiperactiva con el uso de trospio. | |
| MX2022007113A (es) | Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas. | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| MX2024000701A (es) | Metodos de tratamiento de la enfermedad de alzheimer. | |
| MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
| PH12021550741A1 (en) | Vibegron for the treatment of overactive bladder symptoms | |
| MX2021002754A (es) | Tratamiento del autismo y trastornos dentro del espectro del autismo con composiciones de biotina. | |
| MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX2021002590A (es) | Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor. | |
| WO2020005869A3 (en) | Compositions and methods for the treatment of cancer characterized with pcsk9 expression | |
| MX2021003127A (es) | Uso de un inhibidor de catepsina s contra la formacion de anticuerpos antifarmaco. |